68ga-dotanoc and Adenocarcinoma

68ga-dotanoc has been researched along with Adenocarcinoma* in 1 studies

Other Studies

1 other study(ies) available for 68ga-dotanoc and Adenocarcinoma

ArticleYear
Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
    Clinical nuclear medicine, 2018, Volume: 43, Issue:4

    Ga-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like Ga-DOTANOC PET/CT and F-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of Ga-PSMA PET/CT imaging and benefit of Ga-DOTANOC PET/CT and F-FDG PET/CT in such cases.

    Topics: Adenocarcinoma; Aged; Edetic Acid; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neuroendocrine Tumors; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms

2018